Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

23 results
Display

Platelet Function Assay for Clopidogrel and Ticlopidine in Patients With Ischemic Stroke

Kim JG, Lee SJ, Jo SR, Kim JO, Kim HJ, Yun DJ, Ko Y, Oh GS, Lee SJ

  • KMID: 2343402
  • J Korean Neurol Assoc.
  • 2011 Aug;29(3):184-191.
BACKGROUND: The rapid platelet function assay (RPFA) has recently been developed and used to monitor the antiplatelet effects on the P2Y12 ADP receptor. We describe the platelet response to clopidogrel...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Compartment Syndrome Following an Olecranon Fracture in a Stroke Patient Taking Ticlopidine and Aspirin

Lee S, Oh SC, Bae SY

  • KMID: 2323444
  • J Korean Soc Surg Hand.
  • 2011 Dec;16(4):255-258.
We report a case of compartment syndrome following an olecranon fracture in the stroke patient with quadriparesis taking ticlopidine and aspirin. Antithrombic and antiaggregating ability of the medications could increase...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Ticlopidine Induced Bullous Pemphigoid

Lee HY, Baek JO, Lee JR, Kim M, Kim SC, Roh JY

  • KMID: 2247764
  • Korean J Dermatol.
  • 2009 Sep;47(9):1019-1023.
Bullous pemphigoid (BP) is an acquired autoimmune disease that's characterized by subepidermal vesicles and bullae. The etiology for BP is mostly idiopathic, but numerous observations have suggested the role of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A case of ticlopidine induced acute cholestatic hepatitis and pure red cell aplasia

Lee JY, Park EB, Ahn JH, Suh SJ, Jung YK, Kim JH, Shin BK, Yang JH, Yeon JE, Byun KS

Ticlopidine inhibits platelet aggregation and provides beneficial secondary prevention of cerebrovascular and coronary artery disease. Frequently reported adverse effects of ticlopidine include diarrhea, nausea, and rash. However, to our knowledge,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Inhibitory Effect of Ticlopidine on VEGF Induced Corneal Neovascularization

Park YK, Kim MY, Bae SR

  • KMID: 2022140
  • J Korean Ophthalmol Soc.
  • 2003 Jun;44(6):1392-1396.
PURPOSE: Ticlopidine, which has platelet inhibitory property, is currently used in peripheral arterial obstructive disease, ischemic stroke, and coronary artery disease. It is also known to have antiangiogenesis effect. We...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Two cases of pancytopenia induced by ticlopidine

Park CY, Kang JE, Yim HS, Chung CH

  • KMID: 2252759
  • Korean J Med.
  • 2003 Nov;65(Suppl 3):S841-S843.
Ticlopidine is an inhibitor of platelet aggregation used in the management and prevention of thromboembolic disorders. Hematological toxicity is one of the most important side effects of ticlopidine, including neutropenia,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Case of Ticlopidine-induced Cholestatic Hepatitis Which Showed a Prompt Response to Steroid

Kim ES, Woo GH, Kim YS, Lee JW, Moon JS, Kang YK, Lee WJ, Lee JS, Jeon YB, Baik HW

  • KMID: 1647071
  • Korean J Gastroenterol.
  • 2002 Sep;40(3):214-217.
Ticlopidine hydrochloride is a platelet aggregation inhibitor used for the prevention of thromboembolic disease in patients at high risk of stroke, or for the prevention of thrombosis after coronary artery...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Three Cases of Ticlopidine-induced Cholestatic Hepatitis

Kim JH, Kwon YJ, Kim JE, Woo KE, Kim YJ

  • KMID: 2343006
  • J Korean Neurol Assoc.
  • 2002 Jul;20(4):434-436.
Ticlopidine hydrochloride is world-wide used antiplatelet agent that inhibit ADP pathway. Its clinical side effects are the change of the blood picture, allergic skin reaction and gastrointestinal symptoms. We report...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Four cases of ticlopidine-induced cholestatic hepatitis

Han J, Kim MH, Moon HK, Kang KT, Cha KS, Kim YD, Kim JS

  • KMID: 1985130
  • Korean J Med.
  • 2002 Nov;63(5):557-561.
Ticlopidine, a potent antiplatelet agent, is widely used for treatment of coronary artery disease and cerebrovascular disease. Adverse effects has been reported in 10% to 20% of patients receiving ticlopidine....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Randomized Comparison of Cilostazol Versus Ticlopidine Therapy After Elective Coronary Stent Implantaion

Song JH, Yoon C, Rhee I, Jung JY, Jo KH, Kim DI, Kim DS

BACKGROUND: Percutaneous transluminal coronary angioplasty(PTCA) is a widely acceptable treatment for ischemic heart disease. Restenosis after successful PTCA, which develops in 20~30% of all patients, remains a serious late complication....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Case of Aplastic Anemia Associated with Ticlopidine

Lee JY, Shin HE, Kim JS, Lee KS

  • KMID: 2256027
  • Korean J Cerebrovasc Dis.
  • 2001 Mar;3(1):81-82.
Aplastic anemia is a rare side-effect associated with ticlopidine therapy. We report one case of severe aplastic anemia developed after the use of ticlopidine. A 72-year-old woman took ticlopidine at...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Case of Thrombotic Thrombocytopenic Purpura Associated with Ticlopidine

Bae MC, Kim JW, Jang EA, Huh K

  • KMID: 2342847
  • J Korean Neurol Assoc.
  • 2000 Jul;18(4):512-514.
Ticlopidine, a widely used antiplatelet agent, has been rarely reported to cause thrombotic thrombocytopenic purpura (TTP). To the best of our knowledge, its occurrence has never before been reported in...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Effects of cilostazol treatment on angiographic restenosis after coronary stent placement

Chu YH, Park SW, Lee CW, Hong MK, Kim JJ, Kim HS, Cho ST, Lee KS, Nam GB, Choi KJ, Song JK, Kim YH, Park CH, Park SJ

BACKGROUND AND OBJECTIVES: Cilostazol is a potent antiplatelet agent with antiproliferative properties. Few data are available about the effect of cilostazol on post-stenting restenosis. The aim of this study was...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Two Cases of Severe Neutropenia Associated with Ticlopidine

Kim JT, Lee JG, Seo CJ, Shin EK

  • KMID: 2434663
  • Korean Circ J.
  • 1999 Jul;29(7):746-750.
Ticlopidine is a powerful inhibitor of platelet aggregation which is induced by adenosine diphosphate. Ticlopidine has been shown to be effective in reducing combined stroke, myocardial infarction, reocclusion of coronary...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Randomized Comparison of Cilostazol and Ticlopidine after Coronary-artery

Yoon YS, Lee DH, Pyun WB, Kim IJ, Jang Y, Cho SY, Shim WH

  • KMID: 2434655
  • Korean Circ J.
  • 1999 Jul;29(7):688-696.
BACKGROUND AND OBJECTIVES: Combination of ticlopidine and aspirin has been accepted as a standard antiplatelet regimen after coronary stenting because it reduced the rate of cardiac events and hemorrhagic-vascular compli-cations...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparison of Antiplatelet Aggregation Effect between the High-Dose and Low-Dose Ticlopidine: A Preliminary Study

Kim JM, Kim J, Song HJ, Lee HB, Lee TY

  • KMID: 1812889
  • J Korean Neurol Assoc.
  • 1999 May;17(3):347-351.
BACKGROUND: To investigate the efficacy of antiplatelet activity of low dose ticlopidine, we compared the antiplatelet effect of low dose ticlopidine with a high dose. METHODS: Fourteen healthy volunteers were...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Effects of Anti-Platelet Agents in Preventing Coronary Stent Restenosis

Bae Y, Jeong MH, Kim NH, Park HW, Kang KT, Lee SH, Park WS, Cho JH, Kim SH, Kim JW, Ahn YK, Cho JG, Park CS, Park JC, Kang JC

BACKGROUND: Restenosis is still remained as the most important limitation in clinical practice with coronary stent. Experimental study in a porcine model and clinical study in patients with coronary artery...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical and Angiographic Outcomes: Subcutaneous Nadroparin versus Ticlopidine after Coronary Stenting

Shin KD, Chae JK, Moon SK, Kim WH, Ko JK

BACKGROUNG AND OBJECTIVES: It was reported that low molecular weight heparin (LMWH) was more effective than unfractionated heparin in patients with acute coronary syndrome. Recent studies have shown that the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Two cases of Ticlopidine-induced neutropenia in patients with cardiovascular disease

Chae GS, Yoo HS, Jee JH, Lee JM, Ahn JS, Lee JA, Park YS, Doo YC, Han KR, Oh DJ, Rhim CY

Ticlopidine is an antiplatelet agent used as a drug to prevent the recurrence of cerebral infarction or ischemic heart disease. Close attention has recently been paid to the superiority of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparative study of triflusal and ticlopidine on anti-platelet aggregatory effect and side effects

Kim HG, Kim JS, Lee MC

  • KMID: 1546747
  • J Korean Neurol Assoc.
  • 1998 Feb;16(1):21-27.
BACKGROUND AND PURPOSE: Platelet aggregation plays an important role in thrombogenesis. Thus antiplatelet agents, such as aspirin and ticlopidine, have been in usage to prevent for recurrent ischemic stroke. Triflusal...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr